Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 72.61% | 47.76% | 51.28% | 126.41% | 175.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.61% | 47.76% | 51.28% | 126.41% | 175.70% |
| Cost of Revenue | 17.14% | 58.71% | 31.80% | 97.54% | 214.49% |
| Gross Profit | 81.15% | 46.44% | 53.85% | 130.49% | 170.56% |
| SG&A Expenses | 17.78% | 16.09% | 21.20% | 39.57% | 23.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.85% | 16.07% | 5.67% | 159.15% | 28.70% |
| Operating Income | 0.02% | 0.15% | 13.14% | -166.29% | 1.99% |
| Income Before Tax | -4.69% | -0.43% | 31.95% | -170.36% | 2.49% |
| Income Tax Expenses | -145.92% | -193.48% | -- | -- | -- |
| Earnings from Continuing Operations | -3.98% | 1.18% | 30.92% | -170.94% | 2.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.98% | 1.18% | 30.92% | -170.94% | 2.02% |
| EBIT | 0.02% | 0.15% | 13.14% | -166.29% | 1.99% |
| EBITDA | -0.06% | 0.03% | 13.16% | -167.85% | 1.95% |
| EPS Basic | -3.06% | 3.73% | 33.02% | -155.47% | 6.85% |
| Normalized Basic EPS | -0.64% | 5.05% | 36.57% | -154.91% | 7.27% |
| EPS Diluted | -3.06% | 3.73% | 33.02% | -155.47% | 6.85% |
| Normalized Diluted EPS | -0.64% | 5.05% | 36.57% | -154.91% | 7.27% |
| Average Basic Shares Outstanding | 4.03% | 5.78% | 7.29% | 6.06% | 5.17% |
| Average Diluted Shares Outstanding | 4.03% | 5.78% | 7.29% | 6.06% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
